Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

U.S. FTC requires Amneal and Impax to divest rights to 10 generic drugs

WASHINGTON (Reuters) - The U.S. Federal Trade Commission said on Friday it would require Impax Laboratories Inc and privately held Amneal Pharmaceuticals LLC to divest rights to 10 generic medications as a condition of their merger.

The FTC said that under the terms of the proposed settlement ANI Pharmaceuticals Inc will acquire seven products, Perrigo Company Plc will acquire Impax's rights to two products that it had partnered with Impax to manufacture and sell, and G&W Laboratories Inc will acquire Impax's marketing rights to one product that G&W manufactures for Impax.

(Reporting by Eric Beech; Editing by Lisa Lambert)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.